Estrella Immunopharma, Inc.
ESLA
$0.7936
-$0.0428-5.12%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 12.69% | 34.21% | 35.58% | -21.49% | -138.54% |
| Total Depreciation and Amortization | -- | -- | -200.00% | -200.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -100.00% | 191.67% | 280.05% | 366.66% | 600.51% |
| Change in Net Operating Assets | -213.68% | -206.22% | -259.99% | -208.39% | 350.21% |
| Cash from Operations | -3,423.89% | -1,102.63% | -612.74% | -420.42% | 77.01% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,416.61% | 1,917.07% | 3,634.14% | -- | -- |
| Cash from Investing | 1,416.61% | 1,917.07% | 3,634.14% | -- | -- |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | 66,566.67% | 66,566.67% | 66,566.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -- | 80.40% | 80.40% | 80.40% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -309.97% | -- | -- | -844.36% | 269.99% |
| Cash from Financing | -136.93% | -- | 160.50% | 156.69% | 284.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -206.22% | 204.78% | -22.21% | 114.10% | 540.87% |